Arch Biopartners Inc. (ACHFF)
OTCMKTS · Delayed Price · Currency is USD
0.55608
+0.01928 (3.59%)
At close: Jul 7, 2026
Arch Biopartners Revenue
Arch Biopartners had revenue of 158.08K CAD in the twelve months ending March 31, 2026. In the fiscal year ending September 30, 2025, Arch Biopartners had annual revenue of 275.94K, down -87.00%.
Revenue (ttm)
158.08K CAD
Revenue Growth
-87.00%
P/S Ratio
322.01
Revenue / Employee
n/a
Employees
n/a
Market Cap
36.47M USD
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | 275.94K | -1.85M | -87.00% |
| Sep 30, 2024 | 2.12M | 138.21K | 6.97% |
| Sep 30, 2023 | 1.98M | 1.02M | 105.63% |
| Sep 30, 2022 | 964.68K | -2.92M | -75.18% |
| Sep 30, 2021 | 3.89M | 3.82M | 5,625.22% |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionArch Biopartners News
- 4 weeks ago - Arch Biopartners Featured in American Diabetes Association Thought Leadership Series at the 2026 Scientific Sessions in New Orleans - GlobeNewsWire
- 6 weeks ago - Arch Biopartners announces Royal Columbian Hospital has dosed its first patient in its Phase II cardiac surgery-associated AKI trial - GlobeNewsWire
- 2 months ago - Royal Columbian Hospital begins patient recruitment in Arch Biopartners' Phase II trial of LSALT peptide targeting CS-AKI - GlobeNewsWire
- 3 months ago - Arch Biopartners Closes Non-Brokered Private Placement - GlobeNewsWire
- 3 months ago - Arch Biopartners Arranges Non-Brokered Private Placement - GlobeNewsWire
- 3 months ago - Arch Biopartners and the Fraser Health Authority enter into a Clinical Trial Agreement for the Phase II Cardiac Surgery-Associated AKI Trial - GlobeNewsWire
- 3 months ago - Arch Biopartners Announces St. Michael's Hospital Commences Patient Dosing in the Phase II CS-AKI Trial of LSALT Peptide - GlobeNewsWire
- 5 months ago - Arch Biopartners publishes data linking cytokine IL-32 to inflammation, DKD - TheFly